Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

'Organs-on-chips' wins design award
The 'organ-on-a-chip' technology seeks to revolutionise the way medicines are developed and tested - without the use of animals. 

Technology may significantly reduce need for animal testing

Silicon chips which mimic human organs have won the Design of the Year Award from the Design Museum in London.

Developed by scientists at Harvard University's Wyss Institute, the 'organ-on-a-chip' technology seeks to revolutionise the way medicines are developed and tested - without the use of animals.

As the Wyss Institute explains: “They [organs-on-chips] stand to significantly reduce the need for animal testing by providing a faster, less expensive, less controversial and accurate means to predict whether new drug compounds will be successful in human clinical trials”.

The technology borrows from processes used in the computer chip industry and consists of see-through micro-devices around the size of a fingernail lined with living human cells.

Initial studies have been promising and suggest this technology can accurately replicate the structure, function and behaviour of the gut, liver and lung.

Welcoming the technology, RSPCA's senior scientific officer Barney Reed said: “As well as the significant ethical and animal welfare concerns associated with the use of animals in research, there is currently a lot of discussion relating to the scientific limitations of many traditional animal models and tests. There is a growing acceptance that the system of drug development needs to focus on moving to cheaper, faster and more reliable methods.

“The organs-on-a-chip technology has really caught the imagination and offers a tantalising glimpse of where we might be in just a few years time. A number of pharmaceutical companies are now exploring this stunning new technology to see how they can use it to increase the number of effective medicines and treatments they develop and to significantly reduce the numbers of animals they are using in this process”.

The technology is still in development, but it is hoped that the chips will eventually be linked up to form a 'body-on-a-chip' which can be personalised to the tissues and cells of a particular individual.

Barney concludes: “This wonderful example illustrates what could be achieved when innovative thinkers refuse to accept that there can’t be ‘another way’ of doing things and challenge entrenched thinking and the status quo, and when these progressive visions are given the necessary resourcing”. 

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
Bluetongue RZ extended across Scotland

The Scottish Government has announced an extension to a Bluetongue Restricted Zone that is in place in south-west Scotland.

From 3 October, the Restricted Zone will be extended to cover the whole of Scotland. The Animal, Plant and Health Agency (APHA) says this is in response to further disease spread, as well as simplify trading conditions ahead of the autumn.

Since the whole country will share a disease status, it will no longer be necessary to have a movement license to move susceptible livestock around the country. Restrictions on germinal products remain.

As of 1 October 2026, there were 1,979 cases of BTV-3 in England, 389 cases in Wales and 40 cases in Scotland.